trial

High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia

NCTId NCT01569659
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 101 (actual)
Sponsored by Northwestern University
Primary completion 2015-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
101 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-10
Primary completion
2015-07
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Lurasidone

Sponsors

Northwestern UniversityLead Sponsor
Sumitomo Pharmaceuticals AmericaCollaborator

Investigators

1
Herbert Y Meltzer, MDPrincipal Investigator

Sites

2 total
Chicago, United StatesChicago, United States

Facts & assertions

4 sourced
Enrollment
101
Phase
PHASE4
Primary Completion Date
2015-07
Status
COMPLETED
relationships
The graph out of here
drug
Lurasidone
drug
lead_sponsor
Northwestern University
company
collaborator
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Herbert Y Meltzer, MD
person